Vericel Co. (NASDAQ:VCEL - Get Free Report) has received a consensus rating of "Buy" from the seven analysts that are presently covering the stock, MarketBeat Ratings reports. Seven analysts have rated the stock with a buy rating. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $61.14.
Several research analysts have recently commented on VCEL shares. HC Wainwright reiterated a "buy" rating and issued a $60.00 target price on shares of Vericel in a research report on Friday, February 28th. Truist Financial decreased their target price on Vericel from $61.00 to $51.00 and set a "buy" rating for the company in a research report on Friday, April 11th. Stephens reiterated an "overweight" rating and issued a $67.00 target price on shares of Vericel in a research report on Thursday, May 22nd. Finally, Wall Street Zen lowered Vericel from a "hold" rating to a "sell" rating in a research report on Monday, May 12th.
Read Our Latest Research Report on VCEL
Vericel Stock Performance
Shares of NASDAQ:VCEL traded down $0.10 during mid-day trading on Friday, hitting $43.30. 239,384 shares of the company traded hands, compared to its average volume of 418,173. The firm has a market cap of $2.18 billion, a P/E ratio of 721.79 and a beta of 1.33. Vericel has a 52-week low of $37.39 and a 52-week high of $63.00. The firm's 50 day simple moving average is $41.26 and its 200 day simple moving average is $50.22.
Vericel (NASDAQ:VCEL - Get Free Report) last announced its earnings results on Thursday, May 8th. The biotechnology company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.14). Vericel had a net margin of 1.56% and a return on equity of 1.48%. The company had revenue of $52.60 million for the quarter, compared to analysts' expectations of $53.86 million. During the same quarter in the previous year, the business posted ($0.08) earnings per share. The business's quarterly revenue was up 2.6% compared to the same quarter last year. Equities research analysts expect that Vericel will post 0.14 EPS for the current fiscal year.
Insider Transactions at Vericel
In other news, CEO Dominick Colangelo sold 26,592 shares of Vericel stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $45.78, for a total transaction of $1,217,381.76. Following the transaction, the chief executive officer now owns 259,997 shares in the company, valued at approximately $11,902,662.66. The trade was a 9.28% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 5.20% of the stock is owned by insiders.
Institutional Inflows and Outflows
Several hedge funds have recently bought and sold shares of VCEL. Arcadia Investment Management Corp MI bought a new stake in shares of Vericel during the 4th quarter worth about $48,000. GF Fund Management CO. LTD. bought a new stake in shares of Vericel during the 4th quarter worth about $57,000. Smartleaf Asset Management LLC boosted its stake in shares of Vericel by 511.1% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,265 shares of the biotechnology company's stock worth $70,000 after acquiring an additional 1,058 shares in the last quarter. Meeder Asset Management Inc. boosted its stake in shares of Vericel by 8.4% during the 4th quarter. Meeder Asset Management Inc. now owns 2,357 shares of the biotechnology company's stock worth $129,000 after acquiring an additional 183 shares in the last quarter. Finally, GAMMA Investing LLC boosted its stake in shares of Vericel by 34.8% during the 1st quarter. GAMMA Investing LLC now owns 2,895 shares of the biotechnology company's stock worth $129,000 after acquiring an additional 748 shares in the last quarter.
About Vericel
(
Get Free ReportVericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.
Read More
Before you consider Vericel, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vericel wasn't on the list.
While Vericel currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
